guadecitabine
Showing 1 - 13 of 13
High Risk Myelodysplastic Syndrome Trial in Houston (Guadecitabine)
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- Guadecitabine
-
Houston, TexasM D Anderson Cancer Center
Feb 2, 2022
Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer Trial in United States (Guadecitabine, Carboplatin)
Active, not recruiting
- Small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer
- Guadecitabine
- Carboplatin
-
Indianapolis, Indiana
- +3 more
Feb 14, 2022
Untreated Adult Acute Myeloid Leukemia Trial in Houston (Cladribine, Guadecitabine, Idarubicin)
Completed
- Untreated Adult Acute Myeloid Leukemia
- Cladribine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Apr 28, 2022
Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma Trial in United States (Guadecitabine, Durvalumab)
Active, not recruiting
- Advanced Kidney Cancer
- +2 more
- Guadecitabine
- Durvalumab
-
Chicago, Illinois
- +4 more
Feb 16, 2022
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic
Active, not recruiting
- Extrahepatic Bile Duct Adenocarcinoma, Biliary Type
- +27 more
- Durvalumab
- Guadecitabine
-
Los Angeles, California
- +2 more
Aug 5, 2022
Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome Trial in Worldwide (Guadecitabine)
Terminated
- Acute Myeloid Leukemia
- Myeloid Dysplastic Syndrome
- Guadecitabine
-
Buffalo, New York
- +20 more
Jan 21, 2022
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary
Suspended
- Locally Advanced Unresectable Primary Central Chondrosarcoma
- +2 more
- Belinostat
- +5 more
-
Phoenix, Arizona
- +38 more
Feb 2, 2023
Colorectal Adenocarcinoma, CpG Island Methylator Phenotype, Metastatic Microsatellite Stable Colorectal Carcinoma Trial in Los
Withdrawn
- Colorectal Adenocarcinoma
- +7 more
- Guadecitabine
- Nivolumab
-
Los Angeles, California
- +1 more
Apr 1, 2021
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +5 more
- Atezolizumab
- +4 more
-
Tucson, Arizona
- +16 more
Oct 19, 2022
MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (Guadecitabine, Treatment Choice)
Completed
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Guadecitabine
- Treatment Choice
-
Duarte, California
- +95 more
Sep 1, 2021
Acute Myeloid Leukemia Trial in Worldwide (guadecitabine, Treatment Choice (TC))
Completed
- Acute Myeloid Leukemia
- guadecitabine
- Treatment Choice (TC)
-
Los Angeles, California
- +94 more
Sep 5, 2021
MDS, Acute Myeloid Leukemia Trial in France (Guadecitabine)
Unknown status
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Guadecitabine
-
Angers, France
- +11 more
Nov 13, 2018